Mouse Osteoprotegerin,OPG ELISA KIT

Code CSB-E04693m
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


This Mouse TNFRSF11B ELISA Kit was designed for the quantitative measurement of Mouse TNFRSF11B protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 15.6 pg/mL-1000 pg/mL and the sensitivity is 3.9 pg/mL.

Target Name tumor necrosis factor receptor superfamily, member 11b
Alternative Names
Tnfrsf11b ELISA Kit; Ocif ELISA Kit; Opg ELISA Kit; Tumor necrosis factor receptor superfamily member 11B ELISA Kit; Osteoclastogenesis inhibitory factor ELISA Kit; Osteoprotegerin ELISA Kit
Abbreviation TNFRSF11B
Uniprot No. O08712
Species Mus musculus (Mouse)
Sample Types serum, plasma, tissue homogenates
Detection Range 15.6 pg/mL-1000 pg/mL
Sensitivity 3.9 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cell Biology
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of mouse OPG in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:5 Average % 87
Range % 83-90
1:10 Average % 102
Range % 98-106
1:20 Average % 85
Range % 81-89
1:40 Average % 97
Range % 93-100
The recovery of mouse OPG spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 85 81-89
EDTA plasma (n=4) 96 92-99
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1000 2.045 2.102 2.074 1.938
500 1.357 1.308 1.333 1.197
250 0.879 0.915 0.897 0.761
125 0.593 0.578 0.586 0.450
62.5 0.381 0.368 0.375 0.239
31.2 0.275 0.298 0.287 0.151
15.6 0.193 0.187 0.190 0.054
0 0.135 0.137 0.136  
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Gene References into Functions
  1. lactation increases physiological maxillary bone remodeling and orthodontic tooth movement, and both require activation of RANK/RANKL/OPG system PMID: 29382610
  2. Hdac3-depletion in osteoblasts increases expression of Opg, subsequently preserving insulin sensitivity. PMID: 28840938
  3. Epithelial rests of Malassez may be associated with root resorption via OPG, thus helping to explain the mechanism underlying root resorption. PMID: 29644561
  4. findings demonstrate that mTORC1 activation-stimulated RANKL expression in B cells is sufficient to induce bone loss and osteoporosis. The study also established a link between mTORC1 and the RANKL/OPG axis via negative regulation of beta-catenin. PMID: 26825871
  5. RANK/RANKL signaling is involved in the androgen deprivation therapy-induced acceleration of bone metastasis in castration-insensitive prostate cancer and is inhibited by osteoprotegerin to prevent bone metastasis. PMID: 28373003
  6. endocortical resorption is driven by reduced OPG rather than elevated RANKL expression PMID: 27460899
  7. Diabetes significantly increased OPG and the OPG/TRAIL ratio expression in the aorta, while dyslipidemia was the major determinant of the changes observed in the heart, where it significantly increased OPG and reduced TRAIL expression, thus increasing cardiac OPG/TRAIL ratio. PMID: 28070143
  8. These discoveries strongly suggest that Heparan Sulfate plays an active role in regulating OPG-RANKL interaction and osteoclastogenesis. PMID: 27697839
  9. OPG plays an important role in regulating bone marrow mesenchymal stem cells differentiation and bone marrow adipogenesis. PMID: 27898403
  10. These data suggested that OPG played an important role in maintaining the homeostasis of articular cartilage of femoral head. PMID: 27541035
  11. Data show that p38alpha mitogen-activated protein kinase (MAPK) in paired related homeobox 1 protein (Prx1+) bone marrow-derived mesenchymal stromal cells acts to preserve the bone by sustaining osteoprotegerin (OPG) production. PMID: 26947973
  12. OPG expression in chondrocyte increases bone mass in the proximal metaphysis of tibiae through negative regulation of osteoclast formation. PMID: 26329493
  13. the generation of Rag2GFP+ regulatory T cells is unaltered in Tnfrsf11b(-/-) mice PMID: 26254339
  14. identify osteoprotegerin as a HIF target gene capable of directing osteoblast-mediated osteoclastogenesis to regulate bone homeostasis PMID: 25846796
  15. Osteoprotegerin is increased in metabolic syndrome and promotes adipose tissue proinflammatory changes. PMID: 24998520
  16. These results indicate that OPG derived either from the bone marrow or from the vessel wall is sufficient to slow down lesion progression and vascular calcification independent of bone turnover. PMID: 23990207
  17. High concentrations of alendronate decrease the expressions of OPG and RANKL in cultured osteoblasts. PMID: 23268391
  18. In a xenograft model, increased osteoprotegerin expression correlated with a delay to pathologic fracture suggesting a potential role for mTOR inhibitors in the treatment of neuroblastoma bone metastases. PMID: 23331792
  19. Coptisine inhibits RANKL-induced NF-kappaB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells. PMID: 21656335
  20. OPG gene transfer to periodontal tissues could inhibit relapse after orthodontic tooth movement, through the inhibition of osteoclastogenesis PMID: 22196183
  21. Omentin-1 ameliorates arterial calcification and bone loss in vivo through the regulation of the RANK signalling pathway in osteoprotegerin-deficient mice. PMID: 21750093
  22. Increased bone resorption is a noncell autonomous defect, caused by exuberant stimulation of osteo-clastogenesis by Cx43-deficient bone marrow stromal cells, via decreased Opg production. PMID: 21346198
  23. Osteoprotegerin serum levels were decreased in all IL-6 deficient mice and in a highest degree in sham-operated hypothyroid mice. PMID: 21478097
  24. TRAIL and osteoprotegerin are expressed in atherosclerotic plaques in a calcification-prone mouse model PMID: 21426505
  25. RANKL and OPG could have a close relationship with the osteoclast activity during mandibular first molar eruption. PMID: 18788552
  26. distribution of the osteocytic lacunar-canalicular system and osteocyte-secreting molecules--dentin matrix protein 1 and sclerostin--in the epiphyses and cortical bones in osteoprotegerin deficiency PMID: 21079361
  27. overexpression in preosteoblasts promotes their differentiation into mature osteoblasts PMID: 20936961
  28. Co2+ and Cr3+ can stimulate the mRNA expressions of RANKL and osteoprotegerin in osteoblasts. PMID: 20369527
  29. mechanical stretching may play an important role in bone remodeling through the upregulation of OPG and the mechanical signaling leading to OPG induction involves the noncanonical Wnt pathway. PMID: 20200998
  30. Osteoprotegerin(OPG) ex vivo gene therapy may be useful to treat patients for aseptic loosening of prosthetic implants. PMID: 11918293
  31. expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells PMID: 12211438
  32. Osteosclerosis in mice with thrombopoietin overexpression occurs predominantly via up-regulation of osteoprotegerin in host stromal cells leading to disruption of osteoclastogenesis. PMID: 12506018
  33. The presence of OPG on the membrane of these cells was confirmed by western blotting and immunostaining, sRANKL was found to be bound to the OPG on the osteoclast precursors. PMID: 12526098
  34. expression of RANKL and OPG change with age in whole bone and in cultured osteoblast-like cells PMID: 12568404
  35. Runx2 promotes osteoclast differentiation by inducing RANKL and inhibiting OPG PMID: 12697767
  36. osteoprotegerin and RANK ligand have roles in breast cancer bone metastasis PMID: 12923331
  37. bone formation is coupled with bone resorption at local sites in OPG-/- mice, and that serum RANKL levels do not reflect this coupling. PMID: 14500574
  38. OPG secretion is regulated through calmodulin-sensitive protein kinase signaling that depends on the activity of the L-type VSCC and is mediated through the cAMP response element-binding protein. PMID: 14525906
  39. suppression of gene expression affects osteoclastogenic activity of parathyroid hormone PMID: 14969393
  40. Expression in mice with collagen-induced arthritis treated with Kanzo-bushi-to, a Kampo medicine. PMID: 15340228
  41. expression of RANKL and OPG and the formation of osteoclast-like cells do not require Runx2 PMID: 15474477
  42. RANKL inhibitor osteoprotegerin is used to evaluate the role of osteoclast-mediated hypercalcemia in two murine models of hypercalcemia of malignancy. PMID: 15845617
  43. Microorganism-reactive CD4+ T-cells and the RANKL-osteoprotegerin axis provide the molecular basis of the advanced periodontal breakdown in diabetes. PMID: 15855336
  44. findings in OPG knockout mice support the hypothesis that OPG is important in the inhibition of bone remodeling within the otic capsule and the maintenance of normal auditory function PMID: 16467704
  45. Glucocorticoids regulate osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones PMID: 16614077
  46. OPG inhibits advanced plaque progression by preventing an increase in lesion size and lesion calcification. OPG may act as a survival factor and may modulate MMP9 production in vascular cells. PMID: 16840715
  47. microgravity is capable to indirectly stimulate osteoclast formation and activity by regulating osteoblast secretion of crucial regulatory factors such as RANKL and OPG PMID: 16927271
  48. Altogether, these findings suggest that increased OPG production represents an early event in the natural history of diabetes mellitus, possibly contributing to disease-associated endothelial cell dysfunction. PMID: 17148684
  49. OPG suppresses the shedding of RANKL from osteoblasts and the serum RANKL in OPG(-/-) mice exactly reflects the state of bone resorption. PMID: 17182555
  50. bone resorptive action of Dexamethasone is mediated mainly by the inhibition of OPG by transrepressing the OPG gene through the AP-1 site PMID: 17516544

Show More

Hide All

Subcellular Location Secreted.
Tissue Specificity Highly expressed in liver, lung, stomach, intestines and calvaria. Highly expressed in decidua and placenta, and in embryo.
Database Links

KEGG: mmu:18383

STRING: 10090.ENSMUSP00000078705

UniGene: Mm.15383

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1